Targeting ADAM17 inhibits human colorectal adenocarcinoma progression and tumor-initiating cell frequency

Oncotarget

Volumn 8, Issue 39, 2017, Pages 65090-65099

  Dosch, Joseph ^a   Ziemke, Elizabeth ^a   Wan, Shanshan ^a   Luker, Kathryn ^a   Welling, Theodore ^a   Hardiman, Karin ^a   Fearon, Eric ^a   Thomas, Suneetha ^b   Flynn, Matthew ^b   Rios Doria, Jonathan ^b   Hollingsworth, Robert ^b   Herbst, Ronald ^b   Hurt, Elaine ^b   Sebolt Leopold, Judith ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b MEDIMMUNE   (United States)

Author keywords

ADAM17; Colorectal; Notch; Stem cell; TACE

Indexed keywords

ANTINEOPLASTIC AGENT; MEDI 3622; NOTCH RECEPTOR; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ARTICLE; BIOLUMINESCENCE; CANCER GROWTH; CANCER STEM CELL; CARCINOGENESIS; CELL ADHESION; CELL SURVIVAL; COLORECTAL CARCINOMA; CONTROLLED STUDY; CRYOPRESERVATION; FEMALE; GENETIC HETEROGENEITY; HUMAN; LIVER METASTASIS; MOUSE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

EID: 85030090436     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.17780     Document Type: Article

References (21)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61:69-90.
2. Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2014, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2014/, based on November 2016 SEER data submission, posted to the SEER web site, April 2017.
3. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL, and Irinotecan Study Group. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med. 2000; 343:905-14.
4. Merchant NB, Voskresensky I, Rogers CM, Lafleur B, Dempsey PJ, Graves-Deal R, Revetta F, Foutch AC, Rothenberg ML, Washington MK, Coffey RJ. TACE/ADAM-17: a component of the epidermal growth factor receptor axis and a promising therapeutic target in colorectal cancer. Clin Cancer Res. 2008; 14:1182-91.
5. Johnson GR, Saeki T, Gordon AW, Shoyab M, Salomon DS, Stromberg K. Autocrine action of amphiregulin in a colon carcinoma cell line and immunocytochemical localization of amphiregulin in human colon. J Cell Biol. 1992; 118:741-51.
6. Saeki T, Stromberg K, Qi CF, Gullick WJ, Tahara E, Normanno N, Ciardiello F, Kenney N, Johnson GR, Salomon DS. Differential immunohistochemical detection of amphiregulin and cripto in human normal colon and colorectal tumors. Cancer Res. 1992; 52:3467-73.
7. Ciardiello F, Kim N, Saeki T, Dono R, Persico MG, Plowman GD, Garrigues J, Radke S, Todaro GJ, Salomon DS. Differential expression of epidermal growth factor-related proteins in human colorectal tumors. Proc Natl Acad Sci USA. 1991; 88:7792-96.
8. Blanchot-Jossic F, Jarry A, Masson D, Bach-Ngohou K, Paineau J, Denis MG, Laboisse CL, Mosnier JF. Upregulated expression of ADAM17 in human colon carcinoma: co-expression with EGFR in neoplastic and endothelial cells. J Pathol. 2005; 207:156-63.
9. Rios-Doria J, Sabol D, Chesebrough J, Stewart D, Xu L, Tammali R, Cheng L, Du Q, Schifferli K, Rothstein R, Leow CC, Heidbrink-Thompson J, Jin X, et al. A Monoclonal Antibody to ADAM17 Inhibits Tumor Growth by Inhibiting EGFR and Non-EGFR-Mediated Pathways. Mol Cancer Ther. 2015; 14:1637-49.
10. Miyamoto S, Nakanishi M, Rosenberg DW. Suppression of colon carcinogenesis by targeting Notch signaling. Carcinogenesis. 2013; 34:2415-23.
11. Qiao L, Wong BC. Role of Notch signaling in colorectal cancer. Carcinogenesis. 2009; 30:1979-86.
12. Murphy G. The ADAMs: signalling scissors in the tumour microenvironment. Nat Rev Cancer. 2008; 8:929-41.
13. Lu J, Ye X, Fan F, Xia L, Bhattacharya R, Bellister S, Tozzi F, Sceusi E, Zhou Y, Tachibana I, Maru DM, Hawke DH, Rak J, et al. Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of Jagged-1. Cancer Cell. 2013; 23:171-85.
14. Hansen AG, Freeman TJ, Arnold SA, Starchenko A, Jones-Paris CR, Gilger MA, Washington MK, Fan KH, Shyr Y, Beauchamp RD, Zijlstra A. Elevated ALCAM shedding in colorectal cancer correlates with poor patient outcome. Cancer Res. 2013; 73:2955-64.
15. Kyula JN, Van Schaeybroeck S, Doherty J, Fenning CS, Longley DB, Johnston PG. Chemotherapy-induced activation of ADAM-17: a novel mechanism of drug resistance in colorectal cancer. Clin Cancer Res. 2010; 16:3378-89.
16. Das S, Czarnek M, Bzowska M, Mezyk-Kopec R, Stalinska K, Wyroba B, Sroka J, Jucha J, Deneka D, Stoklosa P, Ogonek J, Swartz MA, Madeja Z, Bereta J. ADAM17 silencing in mouse colon carcinoma cells: the effect on tumoricidal cytokines and angiogenesis. PLoS One. 2012; 7:e50791.
17. Göoz P, Göoz M, Baldys A, Hoffman S. ADAM-17 regulates endothelial cell morphology, proliferation, and in vitro angiogenesis. Biochem Biophys Res Commun. 2009; 380:33-38.
18. Zheng X, Jiang F, Katakowski M, Lu Y, Chopp M. ADAM17 promotes glioma cell malignant phenotype. Mol Carcinog. 2012; 51:150-64.
19. Mezyk-Kopec R, Wyroba B, Stalinska K, Próchnicki T, Wiatrowska K, Kilarski WW, Swartz MA, Bereta J. ADAM17 Promotes Motility, Invasion, and Sprouting of Lymphatic Endothelial Cells. PLoS One. 2015; 10:e0132661.
20. Sonoshita M, Itatani Y, Kakizaki F, Sakimura K, Terashima T, Katsuyama Y, Sakai Y, Taketo MM. Promotion of colorectal cancer invasion and metastasis through activation of NOTCH-DAB1-ABL-RHOGEF protein TRIO. Cancer Discov. 2015; 5:198-211.
21. Kranenburg O. Prometastatic NOTCH Signaling in Colon Cancer. Cancer Discov. 2015; 5:115-17.